Skip to content
Invitrocue - Transforming bioanalytics
  • Home
  • About Us
    • Meet Invitrocue
    • Our Team
    • Partners
    • Corporate Governance
    • Careers
  • Oncology
    • Onco-PDO™
    • Patient FAQ
    • Physician FAQ
  • Preclinical Services
    • Overview
    • Drug Metabolism and Pharmacokinetics
    • Toxicology and Safety Assessment
    • Hepatocytes
    • 3D Cell Culture
    • Patient-derived Organoid (PDO)
    • Immunomodulatory Assays
    • Customized Assays and Disease Modelling
    • Invivocue – Humanized Mice
  • Shareholders
    • Reports
      • Financial Reports
      • Analyst Reports
    • Announcements
    • Contact Management
  • News & Resources
    • Publications
    • Conferences & Events
    • Press Releases
    • Privacy Policy
  • Contact Us
  • English
    • English
    • Deutsch
    • Español
    • Português
    • 中文 (中国)
    • 中文 (香港)
  • Home
  • About Us
    • Meet Invitrocue
    • Our Team
    • Partners
    • Corporate Governance
    • Careers
  • Oncology
    • Onco-PDO™
    • Patient FAQ
    • Physician FAQ
  • Preclinical Services
    • Overview
    • Drug Metabolism and Pharmacokinetics
    • Toxicology and Safety Assessment
    • Hepatocytes
    • 3D Cell Culture
    • Patient-derived Organoid (PDO)
    • Immunomodulatory Assays
    • Customized Assays and Disease Modelling
    • Invivocue – Humanized Mice
  • Shareholders
    • Reports
      • Financial Reports
      • Analyst Reports
    • Announcements
    • Contact Management
  • News & Resources
    • Publications
    • Conferences & Events
    • Press Releases
    • Privacy Policy
  • Contact Us
  • English
    • English
    • Deutsch
    • Español
    • Português
    • 中文 (中国)
    • 中文 (香港)

ASX Announcements

Appendix 4G

September 28, 2018

Appendix 4G

Categories ASX Announcements

Notice of Ceasing to be a Substantial Holder

September 10, 2018

Notice of Ceasing to be a Substantial Holder

Categories ASX Announcements

Business updates

September 4, 2018

Business updates

Categories ASX Announcements, News

Preliminary Final Report

August 31, 2018

Appendix 4E for the year ended 30 June 2018

Categories ASX Announcements, Financial Reports

Change in substantial holding

August 28, 2018

Notice of change of interests of substantial holder

Categories ASX Announcements

Appendix 4C – quarterly

July 31, 2018

Appendix 4C – quarterly

Categories ASX Announcements, Financial Reports

Expiry of Unlisted Warrants

July 17, 2018

Expiry of Unlisted Warrants

Categories ASX Announcements

Expiry of Unlisted Warrants

July 2, 2018

Expiry of Unlisted Warrants

Categories ASX Announcements

Cleansing statement

June 28, 2018

Cleansing statement

Categories ASX Announcements

Appendix 3B

June 28, 2018

Appendix 3B OK

Categories ASX Announcements
Post navigation
Older posts
Newer posts
← Previous Page1 … Page6 Page7 Page8 … Page16 Next →

Recent Posts

  • Xylonix and Invitrocue form strategic clinical alliance to validate new method for combating IL-6 pathologies
  • Invitrocue and Angsana partner with Averywell to advance early lung cancer detection across Asia
  • Invitrocue announces merger with Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories
  • Strategic partnership & Financial advisor appointment
  • Invitrocue announces acquisition of Welala to create life science leadership in Thailand and Asean

GET IN TOUCH

51 Science Park Road, #01-11/13 The Aries, Singapore Science Park II Singapore 117586

GENERAL / PHARMACOLOGY ENQUIRIES:

+65 6460 0497
contact@invitrocue.com

ONCO-PDO ENQUIRIES:

+65 6819 0181
onco-pdo@invitrocue.com

SERVICES

Home
About Us
Oncology
Preclinical Services
Investors
News & Resources
Contact Us

Logo Invitrocue
Icon-twitter-x Facebook-f Linkedin-in Youtube

© Copyright 2026 Invitrocue. All rights reserved
Impressum | Privacy Policy | Cookies Policy | Cookie Settings